Mounjaro (Tirzepatide)

tirzepatide, the active ingredient in Mounjaro, is a dual GIP and GLP‑1 receptor agonist presented as a solution for injection for subcutaneous use. It is indicated for the treatment of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control, support weight management, and is approved for use in the European Union.

GNH USA supplies Mounjaro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance and regulatory compliance across all markets.

Mounjaro, a dual GIP and GLP‑1 receptor agonist, is used in the management of type 2 diabetes mellitus.

Type 2 diabetes mellitus: improves glycaemic control and reduces HbA1c levels, often accompanied by weight loss.

Tirzepatide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Vomiting: occasional episodes. - Diarrhea: loose stools. - Decreased appetite: reduced food intake. - Constipation: infrequent hard stools. - Injection site reactions: redness or swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: anaphylaxis, swelling, difficulty breathing. - Thyroid C‑cell tumors: potential risk observed in animal studies. - Renal impairment: worsening kidney function.

When prescribing tirzepatide, clinicians should consider several safety precautions to minimize risk.

Renal function: assess baseline kidney function and monitor periodically. Pancreatitis: discontinue if patient develops persistent abdominal pain. Thyroid disease: avoid in individuals with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Pregnancy and lactation: safety not established; use only if potential benefit justifies risk. Drug interactions: review concomitant medications, especially insulin or sulfonylureas, for hypoglycemia risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tirzepatide can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Insulin: combined use may cause severe hypoglycemia; avoid high‑dose insulin regimens. - Sulfonylureas: increased risk of hypoglycemia; avoid or adjust dose.

Moderate Interactions (Monitor Closely): - Warfarin: tirzepatide may affect INR; monitor coagulation parameters. - Oral contraceptives: possible reduction in efficacy; advise alternative contraception if needed. - Thiazolidinediones: additive gastrointestinal effects; monitor tolerance.